Metraipolis › archive › dc_2bf23f27aa9d

Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response — Europe PMC PMID:42177374

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42177374
DOI
10.1245/s10434-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-10-08T10:48:20.283Z
SHA-256 of the archived text
b06886d0e43085d89a7c15586615a41783787ef447c4433e3f730cd1d81c834e
Stable URL of this page
https://metraipolis.com/documento/dc_2bf23f27aa9d

How to cite

Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response — Europe PMC PMID:42177374 — Europe PMC (en), https://europepmc.org/article/MED/42177374 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2bf23f27aa9d (Metraipolis archive dc_2bf23f27aa9d, sha256 b06886d0e43085d89a7c15586615a41783787ef447c4433e3f730cd1d81c834e)
BibTeX
@misc{dc2bf23f27aa9d,
  title = {Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response — Europe PMC PMID:42177374},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42177374},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2bf23f27aa9d; sha256 b06886d0e43085d89a7c15586615a41783787ef447c4433e3f730cd1d81c834e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42177374. Agents can read the archived copy with the MCP tool read_document.